Considering the different phenotypes of HF at baseline, two parallel trials, EMPEROR-Preserved (NCT03057951 and NCT03619213) and EMPEROR-Reduced (NCT03057977), were conducted to clarify whether the benefits of SGLT2 inhibitors extend to each subset of HF. Here, SLC5A2 is linked to hydrops fetalis.